Clinical trial
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic)…
NCT00102323 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00102323 |
|---|---|
| Title | AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy |
| Official title | A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thrombocytopenia, Idiopathic Thrombocytopenic Purpura |
| Intervention type | Biological, Drug |
| Interventions | Placebo, AMG 531 |
| Enrollment | 63 |
| Start date | Mar 29, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Jan 28, 2005 |
| Last update posted | Nov 7, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: